Business Context and Reporting Period
This Form 8-K is filed by Moleculin Biotech, Inc. (MBRX) on December 15, 2025. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on compliance with Nasdaq listing rules rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency. Previously, on June 27, 2025, the company received a deficiency letter for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. As of December 15, 2025, the company has regained compliance.
Guidance, Outlook, and Risks
Compliance Status: The Nasdaq Listing Qualifications Department confirmed that the company met the Bid Price Rule requirements by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days from December 1, 2025, through December 12, 2025.
Outcome: The matter regarding the listing deficiency is now closed, and the company is in compliance with Nasdaq Listing Rule 5550(a)(2).
Outlook: No forward-looking financial guidance or management commentary regarding future operations is included in this filing.
Investor Verification Checklist
- Verify the current trading price of MBRX common stock to ensure it remains above the $1.00 threshold.
- Confirm the company's continued compliance with other Nasdaq listing requirements beyond the bid price rule.
- Review recent financial statements (10-K or 10-Q) for actual revenue, cash flow, and liquidity data, as this 8-K does not contain such figures.